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Olfactory Identification Testing as a Predictor of the Development of
Alzheimer’s Dementia: A Systematic Review
Gordon H. Sun, MD; Cyrus A. Raji, MD, PhD; Mark P. MacEachern, MLIS; James F. Burke, MD, MS
Objectives/Hypothesis: To evaluate the utility of olfactory identification tests as prognostic instruments for Alzheimer’s
dementia (AD).
Study Design: Systematic review.
Methods: In accordance with PRISMA guidelines, PubMed and Ovid MEDLINE, EMBASE, ISI Web of Science, PsycINFO,
the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials were searched to deter-
mine the quality and quantity of longitudinal and cross-sectional research on this topic.
Results: Two prospective longitudinal cohort studies and 30 cross-sectional studies met inclusion criteria. The prospec-
tive longitudinal studies evaluated subjects with or without mild cognitive impairment (MCI) while also using olfactory identi-
fication testing as part of a neurocognitive evaluation. The first study reported an increased risk of later onset of AD in sub-
jects with baseline hyposmia, whereas the second study suggested a possible relationship between decreased olfaction in
participants with MCI and conversion to AD but was inconclusive due to low follow-up rates. Wide variability in the type of
olfactory identification test used and the reporting of results precluded meta-analysis. The cross-sectional studies demon-
strated a positive association between poorer performance on olfactory identification testing and AD.
Conclusions: Although there is evidence suggesting an association between decreased olfaction and AD, rigorously
designed longitudinal cohort studies are necessary to clarify the value of olfactory identification testing in predicting the
onset of AD.
Key Words: Alzheimer’s disease, mild cognitive impairment, olfaction, smell test, screening, hyposmia, anosmia.
Level of Evidence: 2a.
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INTRODUCTION
Alzheimer’s dementia (AD) is the most common
cause of dementia, with an annual incidence of 1% in
persons aged 60 to 70 years and 6% to 8% in those 85
years of age and older.1 The global prevalence of AD is
estimated at 24 million and is expected to double every
20 years through the year 2040.2 A simple, accurate,
and inexpensive method of predicting the onset of AD
consequently remains a valuable but elusive target for
clinicians. Similarly, early identification of patients with
AD is an important goal for researchers. Early identifi-
cation may enrich clinical trials, which would be better
served by targeting at-risk individuals early in the dis-
ease course or even in a presymptomatic stage.3,4
The association between AD and olfactory impair-
ment has been previously reported.5–7 Accumulation of
amyloid-b plaques and tau protein neurofibrillary tan-
gles throughout the olfactory nervous system appears to
be the most highly supported hypothesis for the mecha-
nism of action.8–11 Olfactory identification tests therefore
are considered promising instruments for diagnosing
AD. A review of 27 clinical olfaction tests found excellent
test-retest reliability scores in several major olfactory
identification tests, such as the 40-item University of
Pennsylvania Smell Identification Test (UPSIT) (r ¼
0.94) and the three-item Pocket Smell Test (PST) (r ¼
0.80).12 The ability of olfactory identification tests to dis-
tinguish between true and false hyposmic patients is
less clearly established. However, the UPSIT can distin-
guish between actual anosmic patients and
malingerers,13,14 whereas the PST has a 99% sensitivity
and 40% specificity for detecting anosmia.15 Other
advantages to olfactory identification testing include
effectiveness in discriminating among varying levels of
olfactory function, low cost, and ease of administration
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compared to other instruments such as olfactory thresh-
old testing.12,16,17
We sought to determine the predictive value of ol-
factory identification tests in the development of AD.
First, we identified the evidence that olfactory identifica-
tion tests predict conversion to AD by obtaining all
longitudinal studies on olfactory identification testing as
a method of detecting incipient AD among adult subjects
with and without baseline mild cognitive impairment
(MCI). As a secondary objective, we characterized the
association between abnormal olfaction as identified by
olfactory identification testing and the diagnosis of AD
by identifying all cross-sectional studies that analyzed
associations between olfactory dysfunction and AD using
olfactory identification tests.
MATERIALS AND METHODS
Search Strategy
We conducted this review using a prespecified protocol,
based on the 2009 Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines.18 An experi-
enced health sciences librarian then conducted a search of
PubMed and Ovid MEDLINE, EMBASE, ISI Web of Science,
PsycINFO, Cochrane Database of Systematic Reviews, and
Cochrane Central Register of Controlled Trials in January
2012. We also reviewed reference lists of review articles and
other relevant publications, including manuscripts accessed
through the Cochrane Database of Systematic Reviews, for
additional studies. Conference proceedings and abstracts, data-
bases of gray literature or unpublished data, and non-English
publications were not considered for review due to limited
resources. A full description of the search strategy and
complete list of the search terms and limits used in each
database are included in the online Supplementary Appendix.
Citations were imported into EndNote (Thomson Reuters, New
York, NY). The combined database searches yielded 2,067
citations, of which 893 duplicate records were removed prior to
formal review.
Study Selection
Two authors reviewed all articles for inclusion, with dis-
agreements being resolved by discussion between the reviewers.
Our primary objective was to describe the predictive value of ol-
factory identification testing for conversion to AD by reviewing
prospective clinical trials and longitudinal observational stud-
ies. Longitudinal studies were considered more important in
this review than cross-sectional analyses because the former
track changes in patient populations over time and represent
the gold standard study design to assess the value of prognostic
information, whereas cross-sectional analyses demonstrate sim-
ple associations and are more susceptible to confounding.19
Inclusion criteria included the following: initial trial population
including adult patients with baseline normal cognition and/or
MCI, longitudinal development of AD as an outcome, and olfac-
tory identification testing as part of the evaluation of study
participants at both enrollment and follow-up. If the target arti-
cle did not explicitly mention either AD or olfactory
identification testing, or was unclear regarding AD or olfaction
data, it was excluded. Exclusion criteria included the following:
use of olfactory threshold, memory, or recognition testing with-
out olfactory identification testing; retrospective study designs;
publications such as editorials or letters; and study of exclu-
sively non-Alzheimer’s causes of dementia, such as Parkinson’s
disease (PD) or vascular dementia. Articles available before
1984 were excluded because the first olfactory identification
test (UPSIT) was not published until that year. Studies with
overlapping or duplicate cohorts were excluded.
A secondary analysis was performed to quantify studies
that evaluated the association between AD and impaired olfac-
tory identification testing. All cross-sectional studies that
involved olfactory identification testing and compared normal
subjects or subjects with MCI with subjects diagnosed with AD
were considered eligible. Inclusion criteria were similar, though
clearly longitudinal development of AD as an outcome was no
longer applicable. Exclusion criteria were the same as those
used for longitudinal studies.
Data Extraction and Quality Assessment
The article reviewers independently extracted the follow-
ing data: number of participants, study recruitment setting,
type of olfactory identification test and olfaction data, and inclu-
sion of other neurologic disorders if applicable. For longitudinal
studies, cohort age, gender, and country of origin, duration of
follow-up, and definitions for MCI, AD, and olfactory dysfunc-
tion were also acquired, and the articles themselves were
summarized. The reviewers independently assessed methodolog-
ical quality of longitudinal studies using Quality Assessment
Tool for Diagnostic Accuracy Studies (QUADAS) criteria.20 Dis-
similarities in data extraction and QUADAS scoring were
resolved by discussion between the two reviewers.
RESULTS
The original database literature search yielded
1,174 potential articles (Fig. 1). After the initial round of
screening, 125 articles were obtained for full-text review,
including 10 articles found by manual reference search.
During full-text screening, 93 additional articles were
disqualified. Five studies21–25 were found to have cohorts
identical to or substantially overlapping the cohorts of
the two longitudinal studies that ultimately qualified for
complete analysis.
Summary of Longitudinal Studies
Two longitudinal cohort studies met all inclusion
and exclusion criteria for our primary analysis (Table I).
A total of 217 individuals participated in these studies,
of which 147 were followed longitudinally. Due to the
small number of studies and significant heterogeneity in
study design and reported outcome measures, meta-
analysis was not feasible. Table II includes the olfactory
identification test and the definitions of MCI, AD, and
olfactory dysfunction used in each study.
Devanand et al.26 designed a prospective cohort
study of 148 subjects with MCI to investigate the role of
several baseline diagnostic instruments in predicting con-
version to AD. Inclusion criteria included age between
41 and 85 years, history of cognitive impairment, and Mini-
Mental State Examination (MMSE) score 22/30. Exclusion
criteria included substance abuse or history of stroke or
other neurological or psychiatric diseases.
One hundred twenty-six subjects completed the 3-
year follow-up and were grouped into AD-converters (33/
126, 26.1%) and nonconverters (93/126, 73.8%) for analy-
sis. Baseline assessment revealed no statistically
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significant differences between these subgroups in age,
education, or MMSE scores. After controlling for poten-
tial predictors of conversion to AD, baseline UPSIT
scores were significantly lower among AD-converters
compared to nonconverters (25.8 vs. 33.2, P < .0001).
The authors estimated that UPSIT testing had a sensi-
tivity of 48.5% for predicting the development of AD.
Bahar-Fuchs et al.27 recruited participants in part
from a longitudinal single-center cohort study investigat-
ing brain amyloid positron-emission tomography (PET)
imaging.28 In addition to the 69 subjects drawn from the
PET cohort, three additional subjects were recruited
through other methods. Exclusion criteria included
chronic medical conditions affecting olfactory function or
a medical history suggestive of a non-AD etiology to cog-
nitive dysfunction, such as previous significant head
injury. Olfactory identification testing was conducted
primarily using a subset of six items from the BSIT.
Using the control group’s median olfactory identification
score of 4.5 as the cutoff point for normal olfaction, 23
(92%) MCI patients had olfactory identification impair-
ment at baseline.
Twenty-one subjects without baseline AD (eight
controls and 13 subjects with amnestic MCI [aMCI])
completed full olfactory testing 12 months after enroll-
ment. Six out of 13 (46.1%) aMCI patients met formal
criteria for AD. The conversion rate of participants with
normal cognition to AD was not reported. Among the
subjects with baseline aMCI, AD converters had worse
olfactory identification scores compared to nonconverters
(2.33 vs. 3.44), although this difference was not statisti-
cally significant. Six of the 7 nonconverting aMCI
subjects exhibited significantly lower total olfactory
scores than the control group (P < .001). The proportion
of normal controls who did not notice a subjective
decline in olfactory identification did not differ signifi-
cantly from participants with baseline aMCI or AD who
also did not notice such decline.
Summary of Cross-Sectional Studies
Thirty remaining articles featured cross-sectional
study designs comparing subjects with or without base-
line MCI to subjects with preexisting AD (Table III).
One of these studies29 did follow a large community
cohort of elderly individuals over time, but only pre-
sented olfaction data at follow-up and not at enrollment.
All 30 studies found that participants with baseline AD
had statistically worse olfactory identification scores
(i.e., worse sense of smell) compared to subjects who
were cognitively normal or had baseline MCI. Twenty
studies controlled for age or demonstrated no statisti-
cally significant age differences between normal and AD
subjects on post hoc analysis, whereas two studies
Fig. 1. Study selection flowchart. AD ¼ Alzheimer’s disease; MCI ¼ mild cognitive impairment.
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included controls of both older and younger age. Ten
studies controlled for gender, nine for educational level,
and two for smoking status.
Nine studies concurrently studied subjects with dis-
orders such as PD and vascular dementia. Thirteen
different olfactory identification tests were utilized. The
UPSIT was the most commonly used test, but because
numerical data were presented in a wide variety of
methods, and in many cases were not presented at all,
meta-analysis of studies using the UPSIT alone was not
considered practical.
DISCUSSION
Our systematic review found a large body of evi-
dence establishing an association between hyposmia and
AD. However, for olfactory identification testing to have
clinical or research utility, it must do more than merely
be associated with AD; it must be a useful predictor of
conversion to dementia. We identified no randomized
controlled trials addressing this question and only two
prospective longitudinal studies that suggested that
hyposmia had only moderately predictive value. Deva-
nand et al. did describe an increased risk of developing
AD with baseline hyposmia, but the study by Bahar-
Fuchs et al. failed to find a statistically significant
relationship.
The most straightforward explanation for the asso-
ciation between AD and olfactory dysfunction is that AD
causes olfactory dysfunction. However, this is not the
only possibility. First, the association may be confounded
by other variables that predict both AD and hyposmia.
For example, both AD and hyposmia (in cognitively nor-
mal individuals) increase in frequency with age.30
Although it is plausible that hyposmia may well be
related to abnormal amyloid-b plaque and tau protein
buildup in the olfactory system seen in AD, this relation-
ship could be confounded by other physiologic changes
seen in the elderly, such as decreased hydration and mu-
cous secretion within the olfactory cleft, thinning of the
olfactory mucosa, and prolonged exposure to toxic envi-
ronmental agents.30 The extensive cross-sectional body
of research is particularly susceptible to confounding as
one-third of these studies failed to control for even the
most obvious confounding variable: age. Additionally, as
with all nonexperimental designs, they are susceptible
to confounding by unmeasured variables. Second,
because AD can be challenging to distinguish from other
neurodegenerative disorders that have been associated
with olfactory dysfunction, such as PD, it is possible
that misdiagnosis may misleadingly give rise to an asso-
ciation between olfactory dysfunction and AD.31,32
A limitation of this review was the exclusion of
studies that did not use AD as a primary outcome and
which instead employed specific neuropsychological tests
as surrogate outcome measures of cognitive impairment.
However, these excluded studies were all cross-sectional
TABLE I.
Demographics, Recruitment Strategy, Follow-up, and Methodological Quality of Longitudinal Studies Using Olfactory Identification Testing
as Prognostic Instruments for Alzheimer’s Disease.
Study (Year)
No. of
Starting
Patients
No. of
Patients
Completing
Follow-up Age, yr Male Gender Country Recruitment Strategy
Time to
Follow-up,
mo
QUADAS
Score
Bahar-Fuchs
(2011)27
22 (normal),
25 (MCI),
25 (AD)
8 (normal),
13 (MCI)*
71.7 (normal),
74.4 (MCI)
45.5% (normal),
64% (MCI)
Australia Direct recruitment from
longitudinal PiB-PET
study (69/72 total
subjects)28
12 9
Devanand
(2008)26
148 (MCI) 126 67.2 45% United States Recruitment from a
university-based
memory disorders clinic
36 9
Maximum possible QUADAS score in this review is 14.
*Reasons for limited follow-up cohort (e.g., study dropout) were not published.
QUADAS ¼ Quality Assessment Tool for Diagnostic Accuracy Studies; MCI ¼ mild cognitive impairment; AD ¼ Alzheimer’s dementia; PiB ¼ Pittsburgh
Compound B; PET ¼ positron-emission tomography.
TABLE II.
Neuropathologic Definitions and Olfactory Identification Tests Used in Qualified Longitudinal Studies.
Study (Year) Definition of MCI Definition of AD
Olfactory
Identification
Test
Definition of
Olfactory
Dysfunction
Bahar-Fuchs (2011)27 International Working Group on
MCI consensus criteria
(Petersen criteria)
Probable AD by
NINCDS-ADRDA
criteria
BSIT (full set and
6-question
subset)
<4.5/10 (median score
of control group)
Devanand (2008)26 Two-person consensus diagnosis
using clinical, neuropsychological,
laboratory, and imaging data*
Possible or probable
AD by NINCDS-ADRDA
criteria
UPSIT <32/40
*Study began before MCI criteria were published.
MCI ¼ mild cognitive impairment, AD ¼ Alzheimer’s disease, NINCDS-ADRDA ¼ National Institute of Neurological and Communicative Disorders and
Stroke–Alzheimer’s Disease and Related Disorders Association, BSIT ¼ Brief Smell Identification Test, UPSIT ¼ University of Pennsylvania Smell Identification
Test.
Laryngoscope 122: July 2012 Sun et al.: Olfaction and Alzheimer’s Dementia
1458
TA
B
L
E
II
I.
S
u
m
m
a
ry
o
f
C
ro
s
s
-S
e
c
ti
o
n
a
l
S
tu
d
ie
s
A
n
a
ly
zi
n
g
A
s
so
c
ia
ti
o
n
s
B
e
tw
e
e
n
A
lz
h
e
im
e
r’
s
D
is
e
a
s
e
a
n
d
O
lf
a
c
to
ry
D
y
sf
u
n
c
ti
o
n
.
S
tu
d
y
(Y
e
a
r)
To
ta
l
N
o
.
S
u
b
je
c
ts
N
o
.
N
o
rm
a
l
(C
o
n
tr
o
l)
S
u
b
je
c
ts
N
o
.
M
C
I
S
u
b
je
c
ts
N
o
.
A
D
S
u
b
je
c
ts
S
tu
d
y
S
e
tt
in
g
*
O
lf
a
c
to
ry
Id
e
n
ti
fi
c
a
ti
o
n
Te
s
t
O
lf
a
c
to
ry
S
c
o
ri
n
g
R
e
s
u
lt
s
†
P
V
a
lu
e
C
o
m
m
e
n
ts
C
h
a
n
(2
0
0
2
)4
1
2
4
1
2
0
1
2
C
o
m
m
u
n
it
y
M
o
d
if
ie
d
S
D
O
IT
5
v
s.
2
.7
5
<
.0
1
N
o
n
e
D
jo
rd
je
v
ic
(2
0
0
8
)4
2
1
1
1
3
3
5
1
2
7
A
c
a
d
e
m
ic
U
P
S
IT
3
2
.6
1
v
s
.
1
9
.8
9
<
.0
0
1
N
o
n
e
D
o
ty
(1
9
8
7
)5
6
6
2
5
‡
0
2
5
‡
A
c
a
d
e
m
ic
U
P
S
IT
C
o
n
tr
o
ls
p
e
rf
o
rm
e
d
b
e
tt
e
r
th
a
n
A
D
s
u
b
je
c
ts
o
n
W
ilc
o
x
o
n
s
ig
n
e
d
ra
n
k
te
s
t
(m
e
d
ia
n
s
)
<
.0
0
1
N
o
n
e
F
o
rs
te
r
(2
0
1
0
)4
3
5
2
2
8
0
2
4
A
c
a
d
e
m
ic
S
S
T
1
3
.0
7
v
s
.
7
.5
4
<
.0
0
1
N
o
n
e
G
ra
y
(2
0
0
1
)4
4
3
9
1
3
0
1
3
A
c
a
d
e
m
ic
U
P
S
IT
3
0
v
s
.
1
5
v
s
.
1
2
(m
e
d
ia
n
s
:
c
o
n
tr
o
l
v
s
.
A
D
v
s
.
v
a
s
c
u
la
r
d
e
m
e
n
ti
a
)
.0
0
1
In
c
lu
d
e
s
1
3
s
u
b
je
c
ts
w
it
h
v
a
s
c
u
la
r
d
e
m
e
n
ti
a
J
u
n
g
w
ir
th
(2
0
0
9
)2
9
4
7
8
3
8
8
0
9
0
C
o
m
m
u
n
it
y
P
S
T
1
.8
8
v
s
.
1
.5
6
.0
0
2
N
o
n
e
K
a
re
k
e
n
(2
0
0
1
)4
5
1
5
8
0
7
A
c
a
d
e
m
ic
U
P
S
IT
3
2
.3
8
v
s
.
1
8
.8
6
<
.0
0
1
N
o
n
e
K
e
s
s
la
k
(1
9
8
8
)4
6
6
4
1
8
0
1
8
A
c
a
d
e
m
ic
U
P
S
IT
8
4
.8
1
v
s
.
5
2
.6
6
v
s
.
2
5
.3
3
v
s
.
8
3
.1
7
(n
o
rm
a
liz
e
d
s
c
o
re
s
:
c
o
n
tr
o
l
v
s
.
A
D
v
s.
P
D
v
s
.
M
S
)
<
.0
5
(c
o
n
tr
o
l
v
s.
A
D
)
In
c
lu
d
e
s
1
4
s
u
b
je
c
ts
w
it
h
P
D
a
n
d
1
4
s
u
b
je
c
ts
w
it
h
M
S
K
e
s
s
la
k
(1
9
9
1
)4
7
1
5
7
0
8
A
c
a
d
e
m
ic
U
P
S
IT
9
1
.3
v
s
.
5
9
.7
(n
o
rm
a
liz
e
d
s
c
o
re
s
)
S
ig
n
if
ic
a
n
t
(P
v
a
lu
e
n
o
t
g
iv
e
n
)
N
o
n
e
K
je
lv
ik
(2
0
0
7
)4
8
9
1
5
2
0
3
9
A
c
a
d
e
m
ic
B
S
IT
1
0
v
s
.
6
(m
e
d
ia
n
s
)
<
.0
0
0
5
N
o
n
e
K
n
u
p
fe
r
(1
9
8
6
)4
9
5
5
1
9
0
1
8
A
c
a
d
e
m
ic
3
0
-i
te
m
te
st
2
4
v
s.
1
4
.5
(p
a
ir
s
o
f
s
im
ila
r
s
ti
m
u
li)
,
2
6
v
s
.
1
5
.5
(p
a
ir
s
o
f
d
iff
e
re
n
t
s
ti
m
u
li)
<
.0
0
1
(b
o
th
s
im
ila
r
a
n
d
d
iff
e
re
n
t
s
ti
m
u
li)
In
c
lu
d
e
s
1
8
s
u
b
je
c
ts
w
it
h
v
a
s
c
u
la
r
d
e
m
e
n
ti
a
K
o
s
s
(1
9
8
8
)5
0
2
0
1
0
0
1
0
A
c
a
d
e
m
ic
U
P
S
IT
3
5
.5
v
s.
1
9
<
.0
1
N
o
n
e
L
a
n
g
e
(2
0
0
2
)5
1
1
7
7
7
3
N
o
t
s
p
e
c
if
ie
d
4
8
A
c
a
d
e
m
ic
U
P
S
IT
C
o
n
tr
o
ls
p
e
rf
o
rm
e
d
b
e
tt
e
r
th
a
n
a
ll
o
th
e
r
g
ro
u
p
s
u
s
in
g
F
is
h
e
r
le
a
s
t
s
ig
n
if
ic
a
n
t
d
iff
e
re
n
c
e
te
st
<
.0
0
1
In
c
lu
d
e
s
1
5
s
u
b
je
c
ts
w
it
h
P
D
a
n
d
4
1
s
u
b
je
c
ts
w
it
h
a
m
ix
e
d
g
ro
u
p
o
f
n
e
u
ro
lo
g
ic
d
is
o
rd
e
rs
in
c
lu
d
in
g
M
C
I
L
a
rs
s
o
n
(1
9
9
9
)5
2
2
2
1
1
0
1
1
A
c
a
d
e
m
ic
,
c
o
m
m
u
n
it
y
2
0
-i
te
m
te
st
3
.7
9
v
s
.
2
.3
6
(a
d
ju
s
te
d
s
c
o
re
s
)
<
.0
0
1
N
o
n
e
L
u
zz
i
(2
0
0
7
)5
3
6
0
2
0
0
1
4
A
c
a
d
e
m
ic
O
d
o
u
r
P
e
rc
e
p
ti
o
n
a
n
d
S
e
m
a
n
ti
c
s
B
a
tt
e
ry
1
5
v
s.
6
(o
d
o
r-
to
-p
ic
tu
re
m
a
tc
h
in
g
)
<
.0
0
1
In
c
lu
d
e
s
1
1
s
u
b
je
c
ts
w
it
h
fr
o
n
to
te
m
p
o
ra
l
d
e
m
e
n
ti
a
,
8
s
u
b
je
c
ts
w
it
h
s
e
m
a
n
ti
c
d
e
m
e
n
ti
a
,
a
n
d
7
s
u
b
je
c
ts
w
it
h
c
o
rt
ic
o
b
a
s
a
l
d
e
g
e
n
e
ra
ti
o
n
M
a
k
o
w
s
k
a
(2
0
1
1
)5
4
9
0
6
0
0
3
0
A
c
a
d
e
m
ic
P
S
T
E
ld
e
rl
y
c
o
n
tr
o
ls
p
e
rf
o
rm
e
d
b
e
tt
e
r
th
a
n
A
D
s
u
b
je
c
ts
in
b
o
th
‘‘a
b
so
lu
te
id
e
n
ti
fi
c
a
ti
o
n
’’
a
n
d
‘‘f
o
rc
e
d
c
h
o
ic
e
’’
te
st
s
<
.0
0
1
(e
ld
e
rl
y
c
o
n
tr
o
l
v
s
.
A
D
)
In
c
lu
d
e
s
6
0
c
o
n
tr
o
ls
s
e
p
a
ra
te
d
in
to
3
0
y
o
u
n
g
a
n
d
3
0
e
ld
e
rl
y
s
u
b
je
c
ts
(C
o
n
ti
n
u
e
d
)
Laryngoscope 122: July 2012 Sun et al.: Olfaction and Alzheimer’s Dementia
1459
TA
B
L
E
II
I.
(C
o
n
ti
n
u
e
d
).
S
tu
d
y
(Y
e
a
r)
To
ta
l
N
o
.
S
u
b
je
c
ts
N
o
.
N
o
rm
a
l
(C
o
n
tr
o
l)
S
u
b
je
c
ts
N
o
.
M
C
I
S
u
b
je
c
ts
N
o
.
A
D
S
u
b
je
c
ts
S
tu
d
y
S
e
tt
in
g
*
O
lf
a
c
to
ry
Id
e
n
ti
fi
c
a
ti
o
n
Te
s
t
O
lf
a
c
to
ry
S
c
o
ri
n
g
R
e
s
u
lt
s
†
P
V
a
lu
e
C
o
m
m
e
n
ts
M
c
L
a
u
g
h
lin
(2
0
0
8
)5
5
4
2
1
4
0
1
4
A
c
a
d
e
m
ic
B
S
IT
1
0
.4
v
s.
7
.8
v
s.
7
(c
o
n
tr
o
l
v
s
.
A
D
v
s.
fr
o
n
to
te
m
p
o
ra
l
d
e
m
e
n
ti
a
)
.0
0
1
In
c
lu
d
e
s
1
4
s
u
b
je
c
ts
w
it
h
fr
o
n
to
te
m
p
o
ra
l
d
e
m
e
n
ti
a
M
o
b
e
rg
(1
9
9
7
)5
6
5
6
2
0
0
2
0
A
c
a
d
e
m
ic
U
P
S
IT
,
4
0
-i
te
m
p
ic
tu
re
-b
a
se
d
te
st
3
6
.7
v
s
.
1
8
.4
v
s
.
1
8
.6
(U
P
S
IT
:
c
o
n
tr
o
l
v
s
.
A
D
v
s
.
s
c
h
iz
o
p
h
re
n
ia
),
3
9
.5
v
s.
3
8
.7
v
s
.
3
8
.3
(p
ic
tu
re
-b
a
s
e
d
te
st
:
c
o
n
tr
o
l
v
s.
A
D
v
s
.
s
c
h
iz
o
p
h
re
n
ia
)
.
0
0
1
(b
o
th
U
P
S
IT
a
n
d
p
ic
tu
re
-b
a
se
d
te
st
)
In
c
lu
d
e
s
1
6
s
u
b
je
c
ts
w
it
h
s
c
h
iz
o
p
h
re
n
ia
M
o
rg
a
n
(2
0
0
2
)5
7
2
4
1
2
0
1
2
A
c
a
d
e
m
ic
U
P
S
IT
,
S
D
O
IT
3
5
v
s
.
1
7
(U
P
S
IT
),
5
.4
v
s
.
2
.4
(S
D
O
IT
)§
<
.0
0
1
(b
o
th
U
P
S
IT
a
n
d
S
D
O
IT
)
N
o
n
e
M
o
to
m
u
ra
(2
0
0
6
)5
8
5
3
3
0
0
1
2
A
c
a
d
e
m
ic
B
S
IT
9
.4
v
s
.
3
.5
v
s
.
6
.8
(c
o
n
tr
o
l
v
s
.
A
D
v
s.
v
a
s
c
u
la
r
d
e
m
e
n
ti
a
)
<
.0
1
(c
o
n
tr
o
l
v
s.
A
D
)
In
c
lu
d
e
s
1
1
s
u
b
je
c
ts
w
it
h
v
a
s
c
u
la
r
d
e
m
e
n
ti
a
M
u
rp
h
y
(2
0
0
3
)5
9
3
5
2
2
0
1
3
A
c
a
d
e
m
ic
S
D
O
IT
6
2
%
v
s.
2
7
%
c
o
rr
e
c
t
S
ig
n
if
ic
a
n
t
(P
v
a
lu
e
n
o
t
g
iv
e
n
)
N
o
n
e
P
e
n
tz
e
k
(2
0
0
7
)6
0
7
0
3
0
0
2
0
A
c
a
d
e
m
ic
,
c
o
m
m
u
n
it
y
S
S
T
1
3
v
s
.
6
.1
5
v
s.
1
3
.4
(c
o
n
tr
o
l
v
s
.
A
D
v
s.
d
e
p
re
s
s
io
n
)
<
.0
0
1
In
c
lu
d
e
s
2
0
s
u
b
je
c
ts
w
it
h
d
e
p
re
s
s
io
n
P
e
te
rs
(2
0
0
3
)6
1
3
0
8
8
1
4
A
c
a
d
e
m
ic
1
6
-i
te
m
te
s
t
1
2
.6
3
v
s
.
1
0
.5
v
s
.
1
0
.0
7
(c
o
n
tr
o
l
v
s.
M
C
I
v
s.
A
D
)
.0
4
N
o
n
e
R
e
ze
k
(1
9
8
7
)6
2
4
4
2
6
0
1
8
A
c
a
d
e
m
ic
5
-i
te
m
te
s
t
2
.9
v
s.
0
.3
(in
6
0
to
7
0
y
e
a
r
o
ld
s
),
2
.7
v
s.
0
.2
(in
7
0
to
8
0
y
e
a
r
o
ld
s
)
<
.0
0
2
(b
o
th
a
g
e
g
ro
u
p
s)
N
o
n
e
R
o
y
e
t
(2
0
0
1
)6
3
4
5
3
0
0
1
5
C
o
m
m
u
n
it
y
1
2
-i
te
m
te
s
t
0
.7
1
7
v
s
.
0
.4
8
3
(a
d
ju
st
e
d
s
c
o
re
s
)
<
.0
0
5
In
c
lu
d
e
s
3
0
c
o
n
tr
o
ls
s
e
p
a
ra
te
d
in
to
1
5
y
o
u
n
g
a
n
d
1
5
e
ld
e
rl
y
s
u
b
je
c
ts
S
e
rb
y
(1
9
9
1
)6
4
1
1
2
5
7
0
5
5
A
c
a
d
e
m
ic
,
c
o
m
m
u
n
it
y
U
P
S
IT
C
o
n
tr
o
ls
(3
1
.8
)
p
e
rf
o
rm
e
d
b
e
tt
e
r
th
a
n
A
D
s
u
b
je
c
ts
b
y
a
g
e
s
u
b
g
ro
u
p
(1
2
.5
-2
0
.3
9
)
<
.0
5
(A
D
s
u
b
g
ro
u
p
c
o
m
p
a
ri
s
o
n
s
)
N
o
n
e
S
te
in
b
a
c
h
(2
0
1
0
)6
5
8
8
2
9
2
9
3
0
A
c
a
d
e
m
ic
S
S
T
1
3
v
s.
9
.3
v
s.
7
.7
<
.0
1
(c
o
n
tr
o
l
v
s.
A
D
),
.0
4
(M
C
I
v
s
.
A
D
)
N
o
n
e
S
u
zu
k
i
(2
0
0
4
)6
6
1
1
5
3
0
0
8
5
A
c
a
d
e
m
ic
B
S
IT
,
6
-i
te
m
p
ic
tu
re
-b
a
se
d
te
st
6
.8
v
s.
4
.1
(B
S
IT
),
4
.4
v
s
.
1
.5
(p
ic
tu
re
-b
a
s
e
d
te
s
t)
<
.0
0
0
1
(b
o
th
B
S
IT
a
n
d
p
ic
tu
re
-b
a
se
d
te
st
)
N
o
n
e
W
a
rn
e
r
(1
9
8
6
)6
7
3
4
1
7
0
1
7
A
c
a
d
e
m
ic
U
P
S
IT
3
0
.2
v
s
.
2
0
.5
<
.0
0
1
N
o
n
e
W
e
s
te
rv
e
lt
(2
0
0
8
)6
8
1
5
3
2
1
8
8
4
4
A
c
a
d
e
m
ic
,
c
o
m
m
u
n
it
y
B
S
IT
1
0
v
s.
8
.5
7
v
s
.
6
.5
(c
o
n
tr
o
l
v
s.
M
C
I
v
s.
A
D
)
<
.0
0
1
(c
o
n
tr
o
l
v
s.
A
D
a
n
d
M
C
I
v
s
.
A
D
)
N
o
n
e
*A
c
a
d
e
m
ic
/c
lin
ic
-b
a
s
e
d
s
tu
d
y
s
e
tt
in
g
s
fo
r
re
c
ru
it
m
e
n
t
in
c
lu
d
e
te
rt
ia
ry
re
fe
rr
a
l
c
e
n
te
rs
.
†
S
c
o
ri
n
g
c
o
m
p
a
ri
s
o
n
s
a
re
n
o
rm
a
l
c
o
n
tr
o
l
s
u
b
je
c
ts
v
e
rs
u
s
A
D
s
u
b
je
c
ts
(in
th
a
t
o
rd
e
r)
a
n
d
m
e
a
n
v
a
lu
e
s
,
u
n
le
s
s
o
th
e
rw
is
e
s
p
e
c
if
ie
d
.
‡
N
in
e
p
a
ti
e
n
ts
fr
o
m
th
e
A
D
c
o
h
o
rt
w
e
re
e
x
c
lu
d
e
d
d
u
e
to
lo
w
s
c
o
re
s
o
n
th
e
P
ic
tu
re
Id
e
n
ti
fi
c
a
ti
o
n
Te
s
t,
a
n
d
th
u
s
n
in
e
m
a
tc
h
e
d
c
o
n
tr
o
ls
w
e
re
a
ls
o
e
x
c
lu
d
e
d
.
T
h
e
re
fo
re
,
2
5
A
D
p
a
ti
e
n
ts
w
e
re
m
a
tc
h
e
d
w
it
h
2
5
c
o
n
tr
o
l
s
u
b
je
c
ts
.
§
O
lf
a
c
to
ry
id
e
n
ti
fi
c
a
ti
o
n
v
a
lu
e
s
w
e
re
e
s
ti
m
a
te
d
fr
o
m
a
fi
g
u
re
in
c
lu
d
e
d
in
th
e
s
tu
d
y,
b
e
c
a
u
s
e
s
p
e
c
if
ic
d
a
ta
w
e
re
n
o
t
p
ro
v
id
e
d
in
th
e
te
x
t.
M
C
I
¼
m
ild
c
o
g
n
it
iv
e
im
p
a
ir
m
e
n
t;
A
D
¼
A
lz
h
e
im
e
r’
s
d
is
e
a
s
e
;
S
D
O
IT
¼
S
a
n
D
ie
g
o
O
d
o
r
Id
e
n
ti
fi
c
a
ti
o
n
Te
s
t;
U
P
S
IT
¼
U
n
iv
e
rs
it
y
o
f
P
e
n
n
s
y
lv
a
n
ia
S
m
e
ll
Id
e
n
ti
fi
c
a
ti
o
n
Te
s
t;
S
S
T
¼
S
n
if
fi
n
’
S
ti
c
k
s
Te
s
t;
P
S
T
¼
P
o
c
k
e
t
S
m
e
ll
Te
s
t;
P
D
¼
P
a
rk
in
s
o
n
’s
d
is
e
a
s
e
;
M
S
¼
m
u
lt
ip
le
s
c
le
ro
si
s
;
B
S
IT
¼
B
ri
e
f
S
m
e
ll
Id
e
n
ti
fi
c
a
ti
o
n
Te
s
t.
Laryngoscope 122: July 2012 Sun et al.: Olfaction and Alzheimer’s Dementia
1460
in design. We did not locate any longitudinal studies
that used surrogate neuropsychological tests as outcome
measures for AD but met all other inclusion criteria.
Several other excluded reports used dementia as a pri-
mary outcome, without explicitly defining Alzheimer’s-
type dementia. Dementia is a generic term that encom-
passes many other neurologic disorders that share
multiple symptoms with AD. A wide range of neurodege-
nerative disorders (e.g., PD, depression) and other
neurologic conditions (e.g., head trauma) are also associ-
ated with hyposmia.7,32–35 Without specifying whether a
given study included AD as a specific subtype, the asso-
ciation between AD and decreased olfaction would have
been artificially inflated. Inclusion of all dementia sub-
types or other neurodegenerative disorders would be
beyond the scope of this project. Another limitation is
the exclusion of gray literature resources, which could
result in research being overlooked. However, we also
recognize that such studies, including conference presen-
tations and abstracts, might have incomplete data and
not be in definitive form. We also believed it unlikely
that a high-quality longitudinal study would not have
remained unpublished; the several abstracts we inciden-
tally encountered during the systematic search
described cross-sectional studies, and many of these
were later recognized as having been formally published
and would have met our exclusion criteria for duplicate
work.
The demand for a rapid, inexpensive, and valid
method of screening at-risk populations for AD has
become increasingly urgent, as large-scale multicenter
projects such as the Alzheimer’s Disease Neuroimaging
Initiative progress forward36 and interest in olfactory
testing crosses over to the lay public.37,38 Cross-sectional
evidence corroborates the association between hyposmia
and AD but does little to validate the use of olfactory
identification as a clinical screening or prognostic instru-
ment. Longitudinal studies of multiethnic, multiregional
community-based cohorts of elderly individuals with
well-characterized cognitive profiles and olfactory data
at baseline and at multiple points over time would be a
better approach, a sentiment shared by other
authors.11,39 Incorporating the new National Institute of
Aging-Alzheimer’s Association diagnostic criteria,40
including the use of cerebrospinal fluid, magnetic reso-
nance imaging, and/or PET biomarkers at follow-up,
would not only sharpen outcome measures but may offer
dementia subtype-specific implications on olfactory iden-
tification testing and its relationship to other emerging
biomarkers. Finally, the use of controls or age- and gen-
der-matched validated normative data as a comparison
standard when scoring olfactory identification tests is
more likely to yield clinically useful outcomes.
CONCLUSION
Olfactory identification testing is a promising, low-
cost, efficient screening tool for AD. The current body of
cross-sectional studies indicates a potential association
between AD and olfactory dysfunction, although using
olfactory data alone to distinguish between AD and
other neurocognitive disorders may not be possible. Fur-
thermore, the predictive value of olfactory dysfunction in
the development of AD is uncertain given the paucity of
longitudinal data. Additional well-designed longitudinal
cohort studies would greatly clarify the role of olfactory
identification testing in the neurocognitive evaluation of
individuals at risk for AD.
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